$3.82
0.14[3.80%]
At close: May 28
$3.82
0[0.00%]
After Hours: 9:29AM EDT
ADC Therapeutics
(NYSE:ADCT)ADC Therapeutics Stock (NYSE:ADCT), Analyst Ratings, Price Targets, Predictions
ADC Therapeutics SA has a consensus price target of $16.33, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Guggenheim on May 7, 2024, April 15, 2024, and April 5, 2024. With an average price target of $5.67 between HC Wainwright & Co., HC Wainwright & Co., and Guggenheim, there's an implied 48.34% upside for ADC Therapeutics SA from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Guggenheim
RBC Capital
TD Cowen
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ADC Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2024 | Buy Now | 109.42% | HC Wainwright & Co. | Robert Burns | $9 → $8 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | 135.6% | HC Wainwright & Co. | Robert Burns | → $9 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | — | Guggenheim | Michael Schmidt | — | Reiterates | → Buy | Get Alert |
| 03/28/2024 | Buy Now | 187.96% | Guggenheim | Michael Schmidt | → $11 | Initiates | → Buy | Get Alert |
| 03/14/2024 | Buy Now | 109.42% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 135.6% | HC Wainwright & Co. | Robert Burns | → $9 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | Buy Now | 109.42% | RBC Capital | Gregory Renza | $6 → $8 | Maintains | Outperform | Get Alert |
| 02/20/2024 | Buy Now | 135.6% | HC Wainwright & Co. | Robert Burns | $3 → $9 | Maintains | Buy | Get Alert |
| 11/20/2023 | Buy Now | -21.47% | HC Wainwright & Co. | Robert Burns | $12 → $3 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | — | TD Cowen | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/08/2023 | Buy Now | 57.07% | RBC Capital | Gregory Renza | $7 → $6 | Maintains | Outperform | Get Alert |
| 09/19/2023 | Buy Now | 214.14% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 109.42% | RBC Capital | Gregory Renza | $9 → $8 | Maintains | Outperform | Get Alert |
| 08/10/2023 | Buy Now | — | JP Morgan | Brian Cheng | — | Upgrade | Underweight → Neutral | Get Alert |
| 08/09/2023 | Buy Now | 135.6% | RBC Capital | Gregory Renza | $10 → $9 | Maintains | Outperform | Get Alert |
| 07/25/2023 | Buy Now | 214.14% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | -47.64% | Morgan Stanley | Jeffrey Hung | $5 → $5 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/20/2023 | Buy Now | 214.14% | HC Wainwright & Co. | Robert Burns | $20 → $12 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 161.78% | RBC Capital | Gregory Renza | $12 → $10 | Maintains | Outperform | Get Alert |
| 04/24/2023 | Buy Now | -47.64% | B of A Securities | Tazeen Ahmad | $7 → $2 | Downgrade | Neutral → Underperform | Get Alert |
| 02/13/2023 | Buy Now | 214.14% | RBC Capital | Gregory Renza | $18 → $12 | Maintains | Outperform | Get Alert |
| 01/24/2023 | Buy Now | 30.89% | Morgan Stanley | Matthew Harrison | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 01/04/2023 | Buy Now | 423.56% | HC Wainwright & Co. | Robert Burns | $21 → $20 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 83.25% | Morgan Stanley | Matthew Harrison | $11 → $7 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | Buy Now | 423.56% | RBC Capital | Gregory Renza | $25 → $20 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 83.25% | B of A Securities | Tazeen Ahmad | $14 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 09/21/2022 | Buy Now | 30.89% | JP Morgan | Brian Cheng | → $5 | Initiates | → Overweight | Get Alert |
| 09/19/2022 | Buy Now | 449.74% | HC Wainwright & Co. | Robert Burns | $20 → $21 | Maintains | Buy | Get Alert |
| 09/09/2022 | Buy Now | 187.96% | Morgan Stanley | Matthew Harrison | $17 → $11 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/22/2022 | Buy Now | 423.56% | HC Wainwright & Co. | Robert Burns | $44 → $20 | Maintains | Buy | Get Alert |
FAQ
What is the target price for ADC Therapeutics (ADCT)?
The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on May 7, 2024. The analyst firm set a price target for $8.00 expecting ADCT to rise to within 12 months (a possible 109.42% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADC Therapeutics (ADCT)?
The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics maintained their buy rating.
When was the last upgrade for ADC Therapeutics (ADCT)?
The last upgrade for ADC Therapeutics SA happened on August 10, 2023 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for ADC Therapeutics SA.
When was the last downgrade for ADC Therapeutics (ADCT)?
The last downgrade for ADC Therapeutics SA happened on November 9, 2023 when TD Cowen changed their price target from N/A to N/A for ADC Therapeutics SA.
When is the next analyst rating going to be posted or updated for ADC Therapeutics (ADCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on May 7, 2024 so you should expect the next rating to be made available sometime around May 7, 2025.
Is the Analyst Rating ADC Therapeutics (ADCT) correct?
While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a maintained with a price target of $9.00 to $8.00. The current price ADC Therapeutics (ADCT) is trading at is $3.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.